Kati Waldenburg

What does successful IR look like? At #COREIR, it’s strategic support that drives visibility and market engagement. Our services include investor engagement, integrated communications, capital markets advisory, and ongoing program management. Learn more: coreir.com/our-services/

@PolaryxTx @NasdaqExchange @WORLDSymposia Congratulations on all the milestones!

These past few weeks have been an exciting whirlwind for the entire #PolaryxTherapeutics team! We kicked off the initial trading of $PLYX common stock on the @NasdaqExchange, presented new data for PLX-200 at the @WORLDSymposia™, announced three key Board members, and wrapped it all up by ringing the @Nasdaq Exchange Closing Bell! The best part is… we’re just getting started. Follow us on @X to stay tuned to our progress as we work together to develop patient-friendly drug candidates for the treatment of #LysosomalStorageDisorders.

Experience the difference with @CoreIR_. #COREIR delivers strategic #IR and #PR support backed by deep market expertise and a commitment to client success. Explore more: coreir.com #COREPR #IR #PR

Welcoming @PolaryxTx [PLYX] to the @NasdaqExchange Closing Bell in celebration of their recent listing. x.com/i/broadcasts/1…

#PolaryxTherapeutics announces that shares of the Company’s common stock have been approved for listing on the @Nasdaq Capital Market under the ticker symbol $PLYX. Shares are expected to commence trading on or about February 2, 2026. Read more: bit.ly/4a3sGRB #Nasdaq

#Polaryx is working to deliver treatments for #lysosomalstoragedisorder patients. Our multi-modal pipeline includes small molecule therapies that aim to promote lysosome biogenesis via PPARα-dependent TFEB upregulation, attenuate neuroinflammation, & enhance neuronal survival. Learn more: polaryx.com

The #COREIR team is excited to attend the Annual @jpmorgan Healthcare Conference alongside many of our clients at this premier healthcare investment event. See you there! #JPM2026

#COREIR's President and Co-Founder, Scott Gordon, shared insights with @commPRObiz on how New Year’s resolution marketing is shifting heading into 2026, with credibility and proven performance taking priority. Read the full article: bit.ly/4szDv6E #EmployeeInsights

The @CoreIR_ team wishes everyone happy holidays! Here’s to a joyful season filled with celebration and good company.

A great night with some of the #COREIR team celebrating a year of collaboration and momentum. Looking ahead to an exciting year! #CompanyCulture

$PSTV's encouraging data presented at @SABCSSanAntonio represents a meaningful step forward in leptomeningeal metastases treatment options. Dr. Andrew Brenner, dives into the key takeaways from #PSTV’s #SABCS25 presentations with @AJMC_Journal in this video interview: ajmc.com/view/phase-1-r… #ClinicalTrial #BreastCancer #Radiotherapeutic #ClinicalTrials #LeptomeningealMetastases #SABCS

Companies partner with @CoreIR_ to drive capital formation, #investorgrowth, and market visibility. From investment theses to press releases, social media, earnings calls, and more, we ensure your message is delivered and understood. Learn more: coreir.com #COREIR

Today, influence and trust matter more than ever. #ThoughtLeadership helps executives and teams shape conversations and build credibility. Read how to amplify your voice and stand out in this edition of #IntheCORE: bit.ly/3L3XZDn #COREIR #COREPR #COREDigital

$PSTV's CEO, Marc Hedrick, M.D., was featured as a key opinion leader in a recent @Nature Cancer article discussing how companies are advancing next-generation #radiopharma treatments ahead of major data readouts. “Plus Therapeutics is using rhenium-186, whose 90-hour half-life and 2- to 4-mm beta-radiation pathlength, plus gamma imaging rays, appear ideal for central nervous system cancers including invasive glioblastomas and leptomeningeal metastases, which can be diffuse and tricky to image...The nature of rhenium-186 radiation — with a longer path length than that of alpha emitters, but higher energy than the slower-decaying beta emitter lutetium — may help to overcome brain tissue’s high radioresistance.” Read the article here: go.nature.com/43pNdxi More about the #radiotherapeutics: bit.ly/4hxVXaI

#PlusTherapeutics' President and CEO, Marc Hedrick, M.D., traveled to the @NasdaqExchange to speak with @RemyBlaireNews of @FintechTvGlobal to discuss @UHC's National Coverage Agreement of @CNSideDx's Cerebrospinal Fluid Assay for #leptomeningealmetastases. Check out the interview below and additional #PSTV video content on our @YouTube page: bit.ly/4mOqced #LeptomeningealCancer #PSTV #CNSide $PSTV @Nasdaq

$KAPA will host a KOL event next Thursday to discuss interim efficacy results from its Phase 2 #clinicaltrial of #ENV105 for advanced #prostatecancer. Register here: bit.ly/3VInPyx PR here: bit.ly/47zNGjx @huntsmancancer @massgeneralnews @harvardmeded #KAPA

The #COREIR team is thrilled to welcome our new SVP #InvestorRelations, Vivian Cervantes! Vivian recently spoke with @Cassatastyle of @cure345 on why healthcare startups need an #AdvisoryBoard and how to properly formulate one. Read her perspective here: bit.ly/45oOwhk

#ICYMI: #KairosPharma announced positive safety results from its ongoing Phase 2 #clinicaltrial of ENV-105 (carotuximab) in patients with metastatic castration-resistant #prostatecancer. Read more: bit.ly/3GYH0jT $KAPA @CedarsSinai, @cityofhope, @huntsmancancer #KAPA

#COREIR delivers integrated communications services that accomplish our client’s communication goals through investor engagement, strategic advisory services​, program management, and much more. Learn more about our full #IR offering: bit.ly/3Uf7BMG #InvestorRelations

.@ProfusaInc's Chairman and CEO, Ben Hwang, Ph.D., joined @SchwabNetwork yesterday to mark the Company successfully listing on @Nasdaq. He discussed $PFSA’s #digitalhealth platform and wearable #biosensor technology. Watch the interview here: bit.ly/46HCn8g #COREClient